Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Patients with Tinnitus (US)

Articles with lock require a subscription to GLG News | Request a free trial
May 13, 2008
Interesting, but be careful with the interpretation
Analysis of: SinuNase Fast-Tracked Pivotal Phase 3 Study in Chronic Sinusitis Shows Statistically Significant Objective Evidence of Superiority of SinuNase Over Control Lavage in Severe Cases | pharmalive.com
Author: GLG Expert Contributor
There are interesting findings presented from the phase 3 study.  However, great care should be used in the analysis as it is fairly easy to spin this in a positive direction which may not correlate with a patient's symptomatic improvement.
March 5, 2008
An issue of prescription coverage
Analysis of: FDA Approves Nexium for Use in Children Ages 1-11 Years | pharmalive.com
Author: GLG Expert Contributor
The approval of the pediatric indication for nexium gives a useful alternative to Prevacid.  However, this is already a crowded field where managed care often dictates which PPI is used.  This will likely steal some market share from Prevacid, but will probably be a small addition to Nexium's...
December 7, 2007
Different Spin On Same Story
Analysis of: Antibiotics and Topical Nasal Steroid for Treatment of Acute Maxillary Sinusitis | jama.ama-assn.org
Author: GLG Expert Contributor
This article highlights the problems facing studies looking at the treatment of acute sinusitis.  Many in big pharma tout excellent efficacy rates for their products treating uncomplicated acute bacterial sinusitis.  In reality, the vast majority of these patients would improve with conservative...
November 8, 2007
The Prevelence of Hearing Impairment in the Middle East
Analysis of: Health-Care Building Booms in Persian Gulf | online.wsj.com
Author: GLG Expert Contributor
There is a cultural intermarriage component of middle eastern life that increases the prevelence of severe to profound hearing impairment in this region.  At a time when the western world is reducing its hearing impaired population, the middle east is at an all time high for hearing loss as a direct...
October 29, 2007
The European Veramyst - but ocular symptom control raises questions
Analysis of: New Allergic Rhinitis Treatment Avamys™ Receives Positive Opinion In Europe | www.medicalnewstoday.com
Author: GLG Expert Contributor
This is the European equivalent of Veramyst.  The control of ocular symptoms is a major marketing push but raises a few questions.  There are concerns regarding cataract formation with the higher potency steroid molecules.  Although low bioavailability is shown, there must be some direct...
June 6, 2007
Don't jump on board too quickly....
Analysis of: Aspire Medical Announces First Implant In US And Start Of Clinical Trial To Treat Sleep Apnea | www.medicalnewstoday.com
Author: GLG Expert Contributor
This product has the potiental to address a very difficult problem for those diagnosed with OSA.  However, OSA is a spectrum of both symptoms and sites of obstruction, and one technique will not be applicable to the population as a whole
May 31, 2007
Managed Care Difficulties
Analysis of: FDA Approves XYZAL(R) (Levocetirizine Dihydrochloride) Tablets For The Relief Of Seasonal And Year Round Allergies, And Chronic Hives | www.medicalnewstoday.com
Author: GLG Expert Contributor
This approval follows the trend of the active metabolite being approved once the original medication goes off-patent.  There is often no additional efficacy, and with more generic alternatives availabe with equal effect, managed care will likely increase pressure to move away from these products...

Page : 11 to 7 of 7

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T17:45:17.637